The stem cell market is estimated at USD 14.7 billion in 2020 and is expected to reach approximately USD 26.4 billion by 2026, recording a CAGR of nearly 10% over the forecast period. The growth of the market is due to increased clinical trials and increased adoption of stem cell therapies worldwide.
In the context of COVID-19, government agencies, research institutes, and many biotech and pharmaceutical companies in various countries are focusing on effective and fast technology for rapid diagnosis of COVID-19. Mesenchymal stem cells are a safe and effective approach to the treatment of COVID-19, according to a 2020 study article published in the scientific journal Aging and Disease (2020). There are at least 10 projects registered in the official international register for clinical trials, suggesting the use of mesenchymal stem cells in patients with coronavirus pneumonia. However, it is still in the early stages of research with respect to the studied market.
A full report of Stem Cells Market available at https://www.orionmarketreports.com/stem-cells-market/10954/
Stem Cells Market – Segmentation
By Product Type
• Adult Stem Cell
• Human Embryonic Cell
• Pluripotent Stem Cell
• Other Product Types
By Application
• Neurological Disorders
• Orthopedic Treatments
• Oncology Disorders
• Injuries and Wounds
• Cardiovascular Disorders
• Other Applications
By Treatment Type
• Allogeneic Stem Cell Therapy
• Auto logic Stem Cell Therapy
• Syngeneic Stem Cell Therapy
Key Players
• CELGENE CORPORATION
• ReNeuron Group plc
• Virgin Health Bank
• Biovault family
• Precious Cells International Ltd
• Mesoblast Ltd
• Caladrius
• Seneca Biopharmaceuticals, Inc.
• Opexa Therapeutics, Inc.
• Pluristem Therapeutics Inc
• STEMCELL Technologies Inc.
• ThermoGenesis Holdings, Inc
• Astellas Pharma Inc.
• Cellular Engineering Technologies
• BioTime, Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
